With this motivation, the groups of Michael Groll at the Technical University of Munich and of Marcus Groettrup at the University of Konstanz have recently solved the crystal structures of both the constitutive proteasome and the immunoproteasome of mice, each with and without the epoxyketone PR957, which is the only selective inhibitor of b5i known so far. In addition, the researchers also solved the structure of the yeast proteasome with and without this inhibitor (Cell (2012), 148, 727-738) .
The detailed analysis of these structures revealed the molecular basis for the specificity of the inhibitor, which turned out to be extremely subtle. The researchers found that a single methionine residue in the immunoproteasome adopts a different conformation than in the constitutive proteasome due to small structural differences in its surroundings. "This distinct conformation is crucial," explains the first author of the paper, Eva Maria Huber. "It results in a larger pocket in the immunoproteasome, which therefore preferentially accommodates bulky amino acids and also the inhibitor. In contrast, constitutive proteasomes harbor a significantly smaller cavity that hampers binding of What does all this mean for disease and drug development? "How the immunoproteasome is mechanistically involved in the pathogenesis of autoimmune diseases is still elusive," says Marcus Groettrup. "The proteasome can perform site-specific cleavages within proteins and release a processed, biologically active polypeptide. We hypothesize that the immunoproteasome may selectively process or degrade a factor which is required for proinflammatory immune responses in autoimmunity."
As yet, only one approved pharmaceutical agent, the cancer drug bortezomib, targets the proteasome, but the authors hope that, on the basis of the detailed structural knowledge they have provided for the whole range of different subunits in the constitutive proteasome and in the immunoproteasome, more specific drugs can be developed to target specific functions of the proteasome. Thus, understanding the complexities of oligomeric proteins will also become very useful knowledge.
Michael Gross is a science writer based at Oxford. He can be contacted via his web page at www.michaelgross.co.uk
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Pieter Roelfsema studied medicine in Groningen, Netherlands between 1983 and 1991 
Why did you go into neuroscience?
At high school I was first attracted to the physical sciences. But I changed my mind because a life surrounded by people seemed more interesting than one surrounded by test tubes. So I decided to study medicine so that I could learn about the science with the prospect of helping patients. The first two years of study, which I did in Groningen, in the north of the Netherlands, were very interesting. From the third year on we learned the mappings between symptoms and diseases. I vividly remember my father giving me the book 'Gödel Escher Bach' by Douglas Hofstadter. It completely changed my perspective. From then on I wanted to know what consciousness is, how we think and remember. I started to read textbooks on neuroscience and then papers. I was fascinated by papers I read on learning and plasticity by Yves Fregnac, Mark Bear and Wolf Singer and I interrupted my medical training to do a student's project on the neurophysiology of snails and then one on learning in rats. I learned a lot in this period, but also came to realize that doing good research is team work. As a novice it seemed to be a good idea to go to a top-level lab. Fernando Lopes da Silva helped me by sending a letter Q & A of recommendation to Wolf Singer at the Max-Planck-Institute in Frankfurt. When I went to Frankfurt for an interview, Singer told me that I should first finish training for my MD degree, but that I would be welcome in his lab afterwards. So I went back to Groningen for two years and finished my clinical training. I was relieved to find out that Singer's offer to join his lab was still valid after these years.
Why did you choose to study 'binding' in visual perception? It was not my own choice. I was attracted to Wolf Singer's lab to study plasticity, but the binding problem -how the brain binds together information about the various features of a particular object which may be processed in separate areas -and the role of oscillatory synchrony had become the major research topic in his lab when I arrived. The scientific climate in the Singer lab was fantastic, with Andreas Engel, Peter König, and later Pascal Fries and many others present. People were excited about the binding problem and we all felt that we were in the middle of a great discovery. For my first project, I recorded from the visual cortex of cats with amblyopia. I was thrilled to record from single neurons that we stimulated with a bar of light using a hand-held lamp, very much as Hubel and Wiesel had done. In my project, we found that cortical neurons connected to the amblyopic eye did not synchronize as well as those connected to the normal eye, supporting the idea of a functional role of synchrony in cortical processing. Later projects focused on the interactions between brain areas where we also observed synchronization. We did realize, however, that one crucial piece of evidence for binding-by-synchrony was lacking: no one had shown that the patterns of synchrony in the visual cortex were correlated with binding in perception.
What has been your biggest research mistake? I am not sure that I would call it a mistake, but the concept of binding-by-synchrony turned out to be wrong. When I went back to Amsterdam in 1995 to work with Henk Spekreijse and Victor Lamme, I was determined to show once and for all that synchrony was responsible for binding in awake monkeys. We used a curvetracing task where monkeys had to determine the end-point of a curvy line, with the idea that this task required perceptual grouping of all line elements. Soon I recorded my first data, and they did not support binding-by-synchrony at all. I had written papers about the importance of synchrony for binding and the negative findings made me worry that my career might be ending. Fortunately, we found that neurons that responded to the line elements that were bound in perception fired more spikes than neurons that responded to irrelevant line elements. Although I briefly thought that I had encountered another problem, because firing-rate differences complicate the analysis of synchrony, I soon realized that we were looking at the neuronal correlates of object-based attention. We later showed that, in other cases, object-based attention also works by labeling a subset of image elements with enhanced neuronal activity. We are now coming to an understanding of binding at a mechanistic, psychological and also neurophysiological level, as an interaction between areas in visual and frontal cortex. As a general lesson one might conclude: it does not matter if your theory is wrong as long as you ask the right question and do the right experiment.
Who are your scientific heroes? I admire Wolf Singer for his attitude towards science; he has been a role model for me. I am also a fan of Shimon Ullman, who is a very original thinker and predicted many insights into visual processing in the 1980s that impacted on my work. Then there is Marvin Minsky. I was very inspired by his books (written with Seymour Papert) about perceptrons (a type of model neural network), Turing machines and consciousness. I was really impressed to learn that he is also the inventor of the confocal microscope.
What is your favorite subject?
Minsky wrote that a real understanding of brains requires us to understand how the mind is built from 'mindless stuff'. Ever since reading Gödel Escher Bach it has been my ambition to understand how thoughts emerge from matter. The curve-tracing task helps, because we see a very nice correspondence between neurophysiology, where the enhanced neuronal activity spreads along a curve, and psychology, where subjects gradually spread objectbased attention along a curve. I like to call this 'thinking along a curve', although others might say that this is not what they call 'thinking'.
The other topic that I have always been very excited about is learning and plasticity. How does the brain reconfigure itself by feedback from the environment? As a medical student I was inspired by the book on 'Parallel Distributed Processing' by Rumelhard and McClelland. Reading this book, I thought it should be possible to train a neuronal network with Hebbian plasticity switched on whenever a reward is given. Back then, I never got my simulated networks to learn anything useful. This changed when I read Sutton and Barto's 1998 book on 'Reinforcement Learning'. This book reviewed many of the insights from the reinforcement literature, and pointed out that the important signal is not the reward itself, but rather the deviations from the reward expectancy. When this insight is combined with what we know about the neurophysiology of attentional signals, very powerful but biologically plausible learning rules can be construed. The beautiful findings of Wolfram Schultz that dopamine cells code precisely such a signal amazed me. I believe that very many important insights into learning will be obtained in the coming years, given the powerful imaging techniques we have nowadays, the new ways to control activity, for example, using optogenetics, and methods for controlling the biochemistry of neurons.
What would be your advice to someone starting a career in biology? First of all, be very selective with the lab that you choose for your PhD project and your first postdoc. Initially concentrate on the techniques and on the questions this lab is good at. Read a lot, especially about the connection between what you do and the things you might want to focus on later so you can start forming your own mature ideas. After having completed one or two studies, start asking your own questions and bend the research in your own direction. And enjoy your time and the freedom of being in science! We are privileged to work on the things that really interest us.
Do you have a publication strategy?
I always tried to publish some of my papers in journals with a high visibility. As a result, they got rejected very often. But as scientists we have a responsibility not only to do good research, but also to make sure that it is read, and having a few high impact papers makes a big difference, if only in obtaining funding for your work. At our institute, we recently discussed the best possible publication strategy with our PhD students. We came to the conclusion that, for the PhD students who want to stay in science, it would also be a good idea to first aim high, because it then becomes easier to get one of the personalized grants that are available for young researchers. I am very glad that there are now many of these grants available, because they help young researchers to develop their own research. Of course, there is a degree of luck in making discoveries so there is no fool-proof way to do it. Do you think about the impact of your work for society? To be honest, I usually chose projects that seemed most interesting from a scientific point of view. But being trained as medical doctor, I think it would be great to bring new knowledge into the clinic. Some of the fundamental insights are finding their way there -for example, I have great expectations for deep-brain stimulation, which has been used to treat Parkinson's disease for many years, but there are many emerging applications in psychiatry. I also believe that neuroscience will help to design a new generation of robots. Scientists are designing new flexible robots, which will perceive and act in the world like animals and knowledge about brains will make the difference in designing their control systems.
